Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
VivaCell Biotechnology specializes in the discovery and development of synthetic or semi-synthetic drug candidates targeting neurovascular and neurodegenerative diseases. The company also provides contract research services using in vitro and ex vivo models to validate health benefits of pharmaceuticals, nutraceuticals, cosmetics, food products, and natural substances. Recent publications highlight work with cannabinoids in fibrosis and inflammation models. The company was acquired by CDMO firm "1Q Health" in April 2025 to expand testing/development capabilities focused on vascular/neurodegenerative disease areas.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on VivaCell Biotechnology.